BridgeBio Oncology Therapeutics Inc. Common Stock (BBOT)
BBOT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | BBOT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001869105 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $76.5M cash; operating cash flow -$37.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 80,251,267 (2026-11-05); 79,988,687 a year earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | 1; latest on 2025-08-13 | Source 2025-08-13 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-09-01 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, San Francisco, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-08-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$34.2M | -$28.4M | $76.5M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | Not filed | -$56.5M | -$44.4M | $54.1M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2026 2026-03-31 | Not filed | -$42.1M | -$35.9M | $52.7M | $716K | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2025 2025-12-31 | Not filed | -$38.8M | -$42.2M | $373.7M | $534K | Needs four quarters | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | Not filed | -$44.8M | -$28.8M | $408.7M | $691K | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | Not filed | -$28.4M | -$23.3M | $31.6M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2025 2025-03-31 | Not filed | -$22.1M | -$19.6M | $26.3M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2024 2024-12-31 | Not filed | -$19.7M | -$15.0M | $30.9M | $483K | Needs four quarters | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-09-01 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 189 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.9% |
| 1 month | -27.5% |
| 3 months | -76.8% |
| Year to date | -82.9% |
| 1 year | -82.7% |
| From 52-week high | -84.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ADCT | ADC Therapeutics SA Common Shares | $1.25 | -6.72% | $159.7M |
| ZNTL | Zentalis Pharmaceuticals Inc. | $1.60 | -5.88% | $157.2M |
| ELDN | Eledon Pharmaceuticals Inc. | $1.97 | -6.86% | $166.4M |
| PRQR | ProQR Therapeutics N.V. | $1.18 | -16.31% | $166.5M |
| PYXS | Pyxis Oncology Inc. | $1.41 | -10.76% | $168.6M |
| ORMP | Oramed Pharmaceuticals Inc. | $3.90 | +5.12% | $169.6M |
| ANTX | AN2 Therapeutics Inc. | $4.47 | -1.76% | $169.6M |
| ABEO | Abeona Therapeutics Inc. | $2.60 | +7.44% | $148.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier